Fortress Biotech Inc (FBIO) — Titan Protect Analysis

FBIO

Fortress Biotech Inc

Healthcare · ·

$2.65

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$87M

Total market value of the company

Trailing P/E

0.81

Very cheap relative to earnings

Forward P/E

-1.48

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.3%

Year-over-year revenue change

Profit Margin

10.8%

How much profit the company keeps from each dollar of revenue

ROE

-108.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+315% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 2 analysts covering this stock

About Fortress Biotech Inc

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular m

https://www.fortressbiotech.com

Country: United States Employees: 78 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.650

Good returns relative to risk taken

Kelly Fraction

0.0181

Marginal edge — very small allocation suggested

Calmar Ratio

0.463

Drawdown risk outweighs the returns — higher risk profile

Annual Return

22.9%

Historical annualised return based on price data

Max Drawdown

-49.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.16

Moves slightly more than the broader market

52W High

$4.53

42% below the year high

52W Low

$1.70

56% above the year low

Avg Volume

422,304

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$3.23

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

108.09

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

48.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-29.8%

Profit from core operations before interest and tax

Free Cash Flow

$-47,286,376

Negative — the business is spending more than it generates

Revenue (TTM)

$63M

Total revenue over the last 12 months

Net Income

$-1,882,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$17.00

Target Median

$11.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go